Gibson Dunn Advises Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings

"Gibson Dunn advised Yarrow Bioscience on its merger with VYNE Therapeutics and on concurrent financings totaling $200 million, representing Yarrow in connection with the transaction."

Gibson Dunn represented Yarrow Bioscience in connection with its merger with VYNE Therapeutics and concurrent $200 million financings. The transaction involves Yarrow Bioscience's merger with VYNE Therapeutics and related financings in an aggregate amount of $200 million. The financings were pursued concurrently with the merger to support the combined transaction. Gibson Dunn represented Yarrow Bioscience with a team composed by: partners Ryan Murr, Melanie Neary, and Branden Berns; and associates Evan Shepherd and Candice Johnson.

Read the full story

Already registered? Login

Gibson Dunn Advises Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads